<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580109</url>
  </required_header>
  <id_info>
    <org_study_id>THERMOEDEME</org_study_id>
    <nct_id>NCT03580109</nct_id>
  </id_info>
  <brief_title>Spa Therapy of Upper Limb Lymphoedema</brief_title>
  <acronym>THERMOEDEME</acronym>
  <official_title>Spa Therapy of Upper Limb Lymphoedema : a Randomized and Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Francaise pour la Recherche Thermale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Floralis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Francaise pour la Recherche Thermale</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The lymphoedema is a chronic disease caused by an insufficiency of lymphatic system. In
      France, 100 000 persons are disabled by this disease.

      The most classic form is the &quot;swollen arm&quot; which affects the women after surgery and
      radiotherapy treatments in breast cancer.

      The lymphoedema is a traditional phlebology indication in spa therapy. The spa therapy linked
      with therapeutic education could constitute a favorable environment for the treatment of arm
      lymphoedema post breast cancer treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THERMOEDEME is a comparative, controlled, randomized, multicenter and simple blinded
      (investigator) trial.

      The aim of this study is to evaluate effects of spa therapy in phlebology with a therapeutic
      education program in daily life of patients suffering lymphoedema post breast cancer
      treatments.

      According to the protocol submitted to authorities in the absence of evidence data on the
      subject, the protocol plans to verify the frequency of success (improvement of LMS27 by 7
      points) after inclusion and follow-up at 6 months of the first 30 patients in order to
      reassess the number of subjects required, if the initial hypothesis were too far from
      reality.

      The replacement of the missing values will be done for each dimension, for the patients who
      answered more than half of the questions, by the average of their answers to the other
      questions of the dimension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 groups :
Immediate spa treatment : the patient realises his spa treatment with education therapeutic soon after the inclusion in study
Late spa treatment : the patient realises his spa treatment linked with education therapeutic after 6 months visit</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The investigator doesn't know in wich group his patient is. The spa treatment is organized by the coordinating center.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of lymphoedema quality of life assessed by the rate of patient with an improvement of the LMS27 scale.</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of patients with an improvement of 7 points minimum of the LMS27 scale (specific quality of life scale in upper limb lymphoedema) at 6 months.
The LMS27 scale is composed of 27 questions with 5 answers possible : never, rarely, sometimes, often, always. The answer's score is respectively 1 (better outcome) to 5 (worse outcome). The higher score is low, the better lymphoedema quality of life is.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of lymphoedema quality of life assessed by the LMS27 scale.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Evolution of the LMS27 scale (specific quality of life scale in upper limb lymphoedema) at 6 and 12 months.
The LMS27 scale is composed of 27 questions with 5 answers possible : never, rarely, sometimes, often, always. The answer's score is respectively 1 (better outcome) to 5 (worse outcome). The higher score is low, the better lymphoedema quality of life is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of lymphoedema quality of life assessed by the most embarrassing items of the LMS27 scale.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Evolution of 5 items the most embarrassing chosen by the patients in the LMS27 scale (specific quality of life scale in upper limb lymphoedema) at 6 and 12 months.
The LMS27 scale is composed of 27 questions with 5 answers possible : never, rarely, sometimes, often, always. The answer's score is respectively 1 (better outcome) to 5 (worse outcome). The higher score is low, the better lymphoedema quality of life is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life assessed by the generic quality of life: Euroquol EQ5D</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Improvement of generic quality of life (the Euroquol EQ5D scale) at 6 and 12 months.
EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of lige that can be used in a wide range of health conditions and treatments. The EQ5D has 6 items intended to measure general health. The top 5 rate mobility, independence, daily activities, pain / discomfort, and anxiety / depression, and are rated according to 3 values from &quot;No problem&quot; to &quot;Problem&quot; or &quot;Incapacity&quot;. This results in an index score. The last item deals with perceived health on the day the questionnaire is filled in and uses a visual analogue scale from 0 (wors) to 100 (best health possible) (Visual Analog Scale Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper limb evaluation</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Evolution of the volume of the upper extremity evaluated (overall and then by segment) from staged perimeter measurements at 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment follow up</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of the costs induced by lymphoedema at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance of spa therapeutic</measure>
    <time_frame>After spa therapy</time_frame>
    <description>Evaluation of the spa therapeutic compliance : number of health care performed in spa therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement educational aims</measure>
    <time_frame>3 months, 9 months.</time_frame>
    <description>Verification of the achievement of educational targets in spa therapy by phone follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of all adverse events attributable to treatment, or not, according to the usual criteria of pharmacovigilance in clinical trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Monthly measurements of functional discomfort from inclusion to 12 months; The functional discomfort is measured monthly by a visual scale : not discomfort to maximal discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the maintenance of benefits at 12 months (stability of the long term effect) on the primary outcome and secondary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect size</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Confirmation of the extent of the effect between 6 and 12 months on the primary outcome and secondary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub group analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Sub group analysis on the primary outcome measure (stratification on primo spa therapy and lymphoedema severity variables)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Lymphedema</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate spa treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late spa treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immediate spa treatment</intervention_name>
    <description>Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)</description>
    <arm_group_label>Immediate spa treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Late spa treatment</intervention_name>
    <description>Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)</description>
    <arm_group_label>Late spa treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women, more than 18 years old

          -  available for a spa treatment (phlebology indication) during 18 days and a follow up
             period of 15 months

          -  with a permanent lymphoedema of upper limb (2 ou 3 stade of International Society for
             Lymphology scale)

          -  voluntary to participate to the study, informed consent form signed after appropriate
             information

          -  affiliation to the social security system or equivalent

        Exclusion Criteria:

          -  cancer undergoing chemotherapy and radiotherapy treatment in primary phase

          -  the baseline score of LMS27 &gt; 79

          -  pain of upper limb linked with a radical plexitis

          -  contra-indication of spa treatment (cancer in progress, psychiatrics disorders,
             immunodeficiency)

          -  Erysipelas case history in the last 6 months or pachyderma and lymphangiectasia

          -  no previous spa treatment for upper limb lymphoedema during the spa year

          -  risk of intensive treatment in the next 6 months

          -  subject participating to an other clinical study interventional

          -  pregnancy, parturient or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick CARPENTIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital University Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire EYCHENNE</last_name>
    <phone>334 76 76 50 40</phone>
    <email>claire.eychenne@univ-grenoble-alpes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole ROLLAND</last_name>
    <phone>334 76 76 69 03</phone>
    <email>carole.rolland@univ-grenoble-alpes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cabinet de médecine vasculaire</name>
      <address>
        <city>Albertville</city>
        <zip>73200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michèle VIONNET FUASSET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simon SOUDET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thermes Argelès-Gazost</name>
      <address>
        <city>Argelès-Gazost</city>
        <zip>65400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thermes Barbotan Les Bains</name>
      <address>
        <city>Barbotan-les-Thermes</city>
        <zip>32150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michèle Fontaine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thermes La Léchère</name>
      <address>
        <city>La Léchère</city>
        <zip>73260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Lourdes</name>
      <address>
        <city>Lourdes</city>
        <zip>65100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sylvie BADENCO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thermes Luz Saint Sauveur</name>
      <address>
        <city>Luz-Saint-Sauveur</city>
        <zip>65120</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cabinet de médecine vasculaire</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Catherine GROSSETETE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Tarbes</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fany GAYRAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julie MALLOIZEL DELAUNAY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique générale HPDA</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Louis DOUBLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Tonkin</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne TISSOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147-54. doi: 10.1196/annals.1413.014. Review.</citation>
    <PMID>18519968</PMID>
  </reference>
  <reference>
    <citation>International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology. 2003 Jun;36(2):84-91. Review.</citation>
    <PMID>12926833</PMID>
  </reference>
  <reference>
    <citation>Carpentier PH, Blaise S, Satger B, Genty C, Rolland C, Roques C, Bosson JL. A multicenter randomized controlled trial evaluating balneotherapy in patients with advanced chronic venous insufficiency. J Vasc Surg. 2014 Feb;59(2):447-454.e1. doi: 10.1016/j.jvs.2013.08.002. Epub 2013 Oct 15.</citation>
    <PMID>24135621</PMID>
  </reference>
  <reference>
    <citation>Pusic AL, Cemal Y, Albornoz C, Klassen A, Cano S, Sulimanoff I, Hernandez M, Massey M, Cordeiro P, Morrow M, Mehrara B. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013 Mar;7(1):83-92. doi: 10.1007/s11764-012-0247-5. Epub 2012 Dec 5. Review.</citation>
    <PMID>23212603</PMID>
  </reference>
  <reference>
    <citation>Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. Expert Rev Pharmacoecon Outcomes Res. 2004 Oct;4(5):581-5. doi: 10.1586/14737167.4.5.581.</citation>
    <PMID>19807551</PMID>
  </reference>
  <reference>
    <citation>Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003 May;41(5):582-92. Review.</citation>
    <PMID>12719681</PMID>
  </reference>
  <reference>
    <citation>Devoogdt N, Lemkens H, Geraerts I, Van Nuland I, Flour M, Coremans T, Christiaens MR, Van Kampen M. A new device to measure upper limb circumferences: validity and reliability. Int Angiol. 2010 Oct;29(5):401-7.</citation>
    <PMID>20924341</PMID>
  </reference>
  <reference>
    <citation>Lymphœdema Framework. Best Practice for the Management of Lymphœdema. International consensus. London: MEP Ltd, 2006:1-54.</citation>
  </reference>
  <reference>
    <citation>Vignes S. [Management of limb lymphedema]. Rev Med Interne. 2012 May;33(5):268-72. doi: 10.1016/j.revmed.2011.12.012. Epub 2012 Jan 31. French.</citation>
    <PMID>22296831</PMID>
  </reference>
  <reference>
    <citation>Carpentier PH, Fabry R. Crénothérapie des maladies vasculaires. In: Queneau P, editor. Médecine Thermale, faits et preuves. Paris: Masson Ed; 2000. p. 102-15.</citation>
  </reference>
  <reference>
    <citation>Carpentier PH, Colomb M, Poensin D, Satger B. [Incidence of erysipelas of the lower limbs in a spa resort. Efficacy of a strategy of sanitation education (La Lechere: 1992-1997)]. J Mal Vasc. 2001 Apr;26(2):97-9. French.</citation>
    <PMID>11319415</PMID>
  </reference>
  <reference>
    <citation>Blaise S, Villemur B, Richaud C, Rastel D, Bucci B, Evra V, Bouchet JY, Satger B; Réseau GRANTED. [Designing a therapeutic education program for patients with lymphedema: live with lymphedema]. J Mal Vasc. 2012 Feb;37(1):1-8. doi: 10.1016/j.jmv.2011.10.006. Epub 2011 Dec 21. French.</citation>
    <PMID>22196687</PMID>
  </reference>
  <reference>
    <citation>Carpentier PH, Satger B, Poensin D, Trens C, Arnold M, Trolliet C, Noilhetas J, Chauvin E, Laurès J Therapeutic education combined with balneotherapy in lymphedema patients. Communication acceptée à l'American Venous Forum (Orlando 25/02/2016, publication en préparation)</citation>
  </reference>
  <reference>
    <citation>Launois R, Alliot F. Quality of Life Scale in Upper Limb Lymphoedema - A validation Study. Lymphology 33, 2000 (Suppl) : 266-74.</citation>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoedema</keyword>
  <keyword>Post breast cancer</keyword>
  <keyword>Spa therapy</keyword>
  <keyword>Education therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

